SEC Filing Summary
Entity note: The supplied filing is Adherex Technologies Inc.’s Form 10-Q, not a filing under the name Fennec Pharmaceuticals Inc. The filing identifies Adherex as a development-stage biopharmaceutical company focused on cancer therapeutics. Amounts below are in U.S. dollars, generally in thousands, unless stated otherwise.
Business context and reporting period
The report covers the quarter and nine months ended September 30, 2013. Adherex reported no product revenue. Its development priorities were sodium thiosulfate (STS), being studied to prevent chemotherapy-related hearing loss, and eniluracil. The company relied on equity and debt financing and stated that it needed additional capital to continue operations.
Financial highlights
| Metric | Q3 2013 / September 30, 2013 | Comparable period / December 31, 2012 |
|---|---|---|
| Revenue | $0 | $0 |
| Operating expenses | $51; includes a research and development credit | $630 in Q3 2012 |
| Net income (loss) | $(1,766); $(0.07) per share | $(764); $(0.03) per share in Q3 2012 |
| Nine-month net income | $734; $0.03 per share | $1,348; $0.05 per share in 2012 |
| Cash and cash equivalents | $538 | $2,303 at December 31, 2012 |
| Total assets / liabilities | $640 / $4,767 | Not provided here for the comparative balance sheet |
| Stockholders’ equity (deficiency) | $(4,127) | $(4,957) at December 31, 2012 |
Net income for the first nine months was driven by a $2,254 unrealized, non-cash gain on derivative liabilities; it should not be read as evidence of operating profitability. In Q3, derivative remeasurement produced a $1,708 non-cash loss. Operating cash use was $1,765 for the first nine months, versus $2,437 in the prior-year period, and $469 in Q3. No cash flow impact arises from derivative remeasurement itself. The filing reports no product revenue, so operating margins are not meaningful.
Current liabilities included a $4,387 derivative liability, primarily warrants denominated in Canadian dollars. The company reported working capital of $260 when derivative liabilities are excluded; including them, current liabilities substantially exceeded current assets. The filing shows no long-term liabilities and does not report conventional outstanding debt at period-end.
Changes versus prior comparable periods
- Q3 operating expenses fell to $51 from $630, principally because eniluracil Phase II trial activity had wound down. Research and development expense was negative $224, reflecting a credit after the company settled an OCT Group payable for less than the accrued amount.
- Despite lower operating expenses, Q3 net loss widened to $1,766 from $764, mainly due to a larger unrealized derivative loss.
- Nine-month operating expenses declined to $1,515 from $2,497, while net income decreased to $734 from $1,348 as the derivative gain was smaller than in 2012.
- Cash fell by $1,765 from year-end, broadly matching nine-month cash used in operations. There was no financing cash inflow during the period.
Outlook, risks, and unusual items
- Going concern: Management stated that substantial doubt existed about the company’s ability to meet obligations as they come due. It said further funding would be required and warned that failure to raise capital could force it to curtail or stop activities.
- Post-period financing: On November 15, 2013, Adherex announced subscription agreements for a private placement of up to $1.6 million, comprising up to 4 million units at $0.40 each. Each unit included a share and a five-year warrant exercisable at $0.50. Closing was expected around November 21, subject to approvals; the filing does not establish that the placement had closed.
- Clinical programs: The COG Phase III STS trial had completed enrollment of 135 children; results were expected to be submitted for presentation in June 2014. SIOPEL had enrolled 80 patients as of November 1, 2013, with interim results also expected to be submitted for presentation in June 2014. Adherex planned to discuss a potential STS New Drug Application data package with the FDA after assessing trial results.
- Eniluracil: Following an FDA end-of-Phase 2 meeting, the FDA recommended considering larger trial designs. Management said the company lacked resources to pursue a larger trial and that further development would require a partner or funding.
- Commitments and contingencies: The OCT service agreement expired June 30, 2013; the company settled a roughly $0.5 million payable for $0.23 million. A new OHSU STS license may require up to $0.1 million upon first commercial sale, with royalties contingent on sales. CEO severance upon termination other than for cause was $140.
- Controls and risks: Management concluded disclosure controls were not effective because one full-time employee handled accounting and financial reporting, creating a material weakness in segregation of duties. Risks also included clinical and regulatory failure, additional financing needs, potential TSX delisting, and limited liquidity in the company’s shares.
Important facts for investors to verify
- Confirm the issuer identity and relationship, if any, between the Adherex filing and Fennec Pharmaceuticals Inc.; the supplied filing names Adherex.
- Verify whether the announced private placement closed, how much was raised, and the resulting share and warrant dilution.
- Assess available cash and expected cash runway against operating needs and the stated going-concern uncertainty.
- Review the COG and SIOPEL STS trial results, timing, and subsequent FDA discussions; verify actual enrollment and data-release status.
- Evaluate the valuation and potential dilution effects of the Canadian-dollar warrants and other outstanding options; the filing reports 18.035 million warrants and 5.814 million options.
- Track remediation of the material weakness in internal controls and any subsequent change in the company’s listing status.